Skip to main content

Table 3 Characteristics of the cluster with Behçet’s disease patients in MHLW registry

From: Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet’s disease in Japan

  Total (n = 6754) Cluster A (n = 1131) Cluster B (n = 876) Cluster C (n = 689) Cluster D (n = 805) Cluster E (n = 1369) Cluster F (n = 799) Cluster G (n = 1085) P
Clinical symptoms used in clustering
 Oral ulcer, n (%) 6336 (93.8) 1050 (92.8) 867 (99.0) 361 (52.4) 805 (100.0) 1369 (100.0) 799 (100.0) 1085 (100.0) < 0.001
 Skin involvement, n (%) 5483 (81.2) 493 (43.6) 755 (86.2) 177 (25.7) 805 (100.0) 1369 (100.0) 799 (100.0) 1085 (100.0) < 0.001
 Eye involvement, n (%) 2344 (34.7) 87 (7.7) 115 (13.1) 538 (78.1) 805 (100.0) 0 (0.0) 799 (100.0) 0 (0.0) < 0.001
 Genital ulcer, n (%) 4242 (62.8) 575 (50.8) 202 (23.1) 212 (30.8) 0 (0.0) 1369 (100.0) 799 (100.0) 1085 (100.0) < 0.001
 Arthritis, n (%) 3311 (49.0) 461 (40.8) 484 (55.3) 192 (27.9) 390 (48.4) 1369 (100.0) 415 (51.9) 0 (0.0) < 0.001
 Gastrointestinal involvement, n (%) 906 (13.4) 879 (77.7) 0 (0.0) 27 (3.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) < 0.001
 Vascular involvement, n (%) 148 (2.2) 0 (0.0) 121 (13.8) 27 (3.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) < 0.001
 Neurological involvement, n (%) 350 (5.2) 0 (0.0) 289 (33.0) 61 (8.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) < 0.001
Other characteristics
 Sex: female/male, n (%) 3990/2764 (59.1/40.9) 654/477 (57.8/42.2) 427/449 (48.7/51.3) 299/390 (43.4/56.6) 295/510 (36.6/63.4) 1032/337 (75.4/24.6) 479/320 (59.9/40.1) 804/281 (74.1/25.9) < 0.001
 Age at onset (years, mean ± SD) 36.68 ± 14.23 39.91 ± 17.73 38.54 ± 14.46 38.78 ± 15.14 36.82 ± 13.09 35.58 ± 12.64 34.45 ± 12.00 33.38 ± 12.37 < 0.001
 Observation period (years, mean ± SD)* 4.14 ± 7.62 4.05 ± 7.71 4.18 ± 7.28 6.32 ± 9.95 3.82 ± 6.91 3.07 ± 6.06 6.19 ± 9.90 2.87 ± 5.57 < 0.001
 Pathergy test, n/available data number (%) 1361/4225 (32.2) 225/706 (31.9) 171/536 (31.9) 117/431 (27.1) 149/404 (29.6) 295/860 (34.3) 175/508 (34.4) 229/680 (33.7) 0.099
 HLA-B51, n/available data number (%) 1389/3141 (44.2) 172/513 (33.5) 237/492 (48.0) 172/358 (48.0) 221/413 (53.5) 244/599 (40.7) 164/321 (51.1) 179/443 (40.4) < 0.001
 Fulfilling ISG criteria, n (%) 4980 (73.7) 405 (35.8) 333 (38.0) 185 (26.9) 805 (100.0) 1368 (99.9) 799 (100.0) 1085 (100.0) < 0.001
 Fulfilling ITR-ICBD criteria, n (%) 5586 (82.7) 657 (58.1) 456 (52.1) 416 (60.4) 805 (100.0) 1368 (99.9) 799 (100.0) 1085 (100.0) < 0.001
 Recent hospitalization, n/available data number (%)** 1556/6002 (25.9) 400/971 (41.2) 299/771 (38.8) 144/625 (23.0) 77/738 (10.4) 271/1195 (22.7) 121/728 (16.6) 244/974 (25.1) < 0.001
  1. ISG International Study Group, ITR-ICBD International Team for the Revision of the International Criteria for Behçet’s Disease
  2. *“Observation period” indicates the period from disease onset to application of specific disease by the Japanese government
  3. **“Recent hospitalization” indicates episode of admission less than 6 months per patients